Article summary
In this conversation with Psychedelic Alpha’s Josh Hardman, Dr. Terence Ching discusses his journey into the field and current work leading Yale’s psilocybin trials for OCD. He reflects on study design considerations, potential mechanisms of action, and some of the subjective phenomena observed during psilocybin sessions in those studies. Dr. Ching also explores what experience and data suggest about integrating psychedelics with evidence-based treatments like CBT and ACT.
Continue to the original publication for the complete article.